Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades

References

• Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 2007; 67: 4244–4253
   PubMed Web of Science ®Google Scholar
• Attard G, Sarker D, Reid A, Molife R, Parker C, de Bono JS. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 2006; 95: 767–774
   PubMed Web of Science ®Google Scholar
• Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L, Richards L. Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001; 11: 1911–1914
   PubMed Web of Science ®Google Scholar
• Bartlett JM, Brawley D, Grigor K, Munro AF, Dunne B, Edwards J. Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. J Pathol 2005; 205: 522–529
   Google Scholar
• Beer TM, Eilers KM, Garzotto M, Hsieh YC, Mori M. Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma. Cancer 2004a; 100: 758–763
   PubMed Web of Science ®Google Scholar
• Beer TM, Garzotto M, Lowe BA, Ellis WJ, Montalto MA, Lange PH, Higano CS. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2004b; 10: 1306–1311
   Google Scholar
• Berry W, Eisenberger M. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 2005; 10: 30–39
   Google Scholar
• Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, Lara PN, Jones S, Taplin ME, Burch PA, Hussain MH, Crawford ED. Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 2006; 24: 2828–2835
   PubMed Web of Science ®Google Scholar
• Brown MD, Gilmore PE, Hart CA, Samuel JD, Ramani VA, George NJ, Clarke NW. Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate 2007; 67: 1384–1396
   PubMed Web of Science ®Google Scholar
• Cabrespine A, Bay JO, Barthomeuf C, Cure H, Chollet P, Debiton E. In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment. Anticancer Drugs 2005; 16: 417–422
   PubMed Web of Science ®Google Scholar
• Calabro F, Sternberg CN. Current indications for chemotherapy in prostate cancer patients. Eur Urol 2007; 51: 17–26
   PubMed Web of Science ®Google Scholar
• Castedo M, Ferri K, Roumier T, Metivier D, Zamzami N, Kroemer G. Quantitation of mitochondrial alterations associated with apoptosis. J Immunol Methods 2002; 265: 39–47
   PubMed Web of Science ®Google Scholar
• Chen BY, Lin DP, Liu JY, Chang H, Huang PH, Chen YL, Chang HH. A mouse prostate cancer model induced by Hedgehog overexpression. J Biomed Sci 2006; 13: 373–384
   PubMedGoogle Scholar
• Chen BY, Liu JY, Chang HH, Chang CP, Lo WY, Kuo WH, Yang CR, Lin DP. Hedgehog is involved in prostate basal cell hyperplasia formation and its progressing towards tumorigenesis. Biochem Biophys Res Commun 2007; 357: 1084–1089
   Google Scholar
• Clarke NW. Management of the spectrum of hormone refractory prostate cancer. Eur Urol 2006; 50: 428–438
   PubMedGoogle Scholar
• Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946–10951
   PubMed Web of Science ®Google Scholar
• Collins AT, Maitland NJ. Prostate cancer stem cells. Eur J Cancer 2006; 42: 1213–1218
   PubMedGoogle Scholar
• Di Lorenzo G, De Placido S. Hormone refractory prostate cancer (HRPC): Present and future approaches of therapy. Int J Immunopathol Pharmacol 2006; 19: 11–34
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438–3444
   PubMed Web of Science ®Google Scholar
• DiPaola RS, Chenven ES, Shih WJ, Lin Y, Amenta P, Goodin S, Shumate A, Capanna T, Cardiella M, Cummings KB, Aisner J, Todd MB. Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma. Cancer 2001; 92: 2065–2071
   Google Scholar
• Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, Zippe C, Fergany A, Klein EA. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63: 1138–1142
   PubMed Web of Science ®Google Scholar
• Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: A randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003; 62: 55–62
   PubMedGoogle Scholar
• Fan L, Pepicelli CV, Dibble CC, Catbagan W, Zarycki JL, Laciak R, Gipp J, Shaw A, Lamm ML, Munoz A, Lipinski R, Thrasher JB, Bushman W. Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology 2004; 145: 3961–3970
   PubMed Web of Science ®Google Scholar
• Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005; 11: 5233–5240
   PubMed Web of Science ®Google Scholar
• Festuccia C, Gravina GL, Angelucci A, Millimaggi D, Muzi P, Vicentini C, Bologna M. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int J Cancer 2005; 115: 630–640
   PubMedGoogle Scholar
• Gignac GA, Morris MJ, Hussain M. Castration resistant, taxane naive metastatic prostate cancer: Current clinical approaches and future directions. J Urol 2007; 178: S30–S35
   Google Scholar
• Gil-Diez de Medina S, Salomon L, Colombel M, Abbou CC, Bellot J, Thiery JP, Radvanyi F, Van der Kwast TH, Chopin DK. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum Pathol 1998; 29: 1005–1012
   PubMed Web of Science ®Google Scholar
• Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007; 67: 4807–4815
   PubMed Web of Science ®Google Scholar
• Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 2004; 90: 449–454
   PubMed Web of Science ®Google Scholar
• Hirst SJ, Barnes PJ, Twort CH. Quantifying proliferation of cultured human and rabbit airway smooth muscle cells in response to serum and platelet-derived growth factor. Am J Respir Cell Mol Biol 1992; 7: 574–581
   PubMed Web of Science ®Google Scholar
• Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 2002; 50: 222–235
   PubMedGoogle Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007; 57: 43–66
   PubMed Web of Science ®Google Scholar
• Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004; 431: 707–712
   PubMed Web of Science ®Google Scholar
• Kasper S, Cookson MS. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 2006; 33: 201–210
   PubMedGoogle Scholar
• Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: A multi-institutional pilot study. J Urol 2007; 177: 1777–1781
   PubMed Web of Science ®Google Scholar
• Lam JS, Reiter RE. Stem cells in prostate and prostate cancer development. Urol Oncol 2006; 24: 131–140
   Google Scholar
• Levitt RJ, Zhao Y, Blouin MJ, Pollak M. The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cancer Lett 2007; 255: 300–306
   Google Scholar
• Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 2007; 109: 2239–2247
   PubMed Web of Science ®Google Scholar
• Man YG, Gardner WA. Focal degeneration of basal cells and the resultant auto-immunoreactions: A novel mechanism for prostate tumor progression and invasion. Med Hypotheses 2008; 70: 387–408
   Google Scholar
• Mathew P, Dipaola R. Taxane refractory prostate cancer. J Urol 2007; 178: S36–S41
   Google Scholar
• Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim JS. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007; 67: 3153–3161
   PubMed Web of Science ®Google Scholar
• Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 2006; 27: 1–22
   PubMedGoogle Scholar
• Mimeault M, Batra SK. Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications. Cancer Metastasis Rev 2007a; 26: 203–214
   Google Scholar
• Mimeault M, Batra SK. Interplay of distinct growth factors during epithelial-mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. Ann Oncol 2007b; 18: 1605–1619
   PubMed Web of Science ®Google Scholar
• Mimeault M, Pommery N, Henichart JP. Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase a inhibitors in human prostatic cancer cell lines. Int J Cancer 2003a; 106: 116–124
   PubMed Web of Science ®Google Scholar
• Mimeault M, Pommery N, Henichart JP. New advances on prostate carcinogenesis and therapies: Involvement of EGF–EGFR transduction system. Growth Factors 2003b; 21: 1–14
   PubMed Web of Science ®Google Scholar
• Mimeault M, Pommery N, Wattez N, Bailly C, Henichart JP. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: Implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 2003c; 56: 1–12
   PubMed Web of Science ®Google Scholar
• Mimeault M, Jouy N, Depreux P, Henichart JP. Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines. Prostate 2005; 62: 187–199
   PubMed Web of Science ®Google Scholar
• Mimeault M, Moore E, Moniaux N, Henichart JP, Depreux P, Lin MF, Batra SK. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int J Cancer 2006; 118: 1022–1031
   PubMedGoogle Scholar
• Mimeault M, Hauke R, Mehta PP, Batra SK. Recent advances on cancer stem/progenitor cell research: Therapeutic implications for overcoming resistance to the most aggressive cancers. J Mol Cell Med 2007a; 11: 980–1010
   Google Scholar
• Mimeault M, Johansson SL, Venkatraman G, Moore E, Henichart JP, Depreux P, Lin MF, Batra SK. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther 2007b; 6: 967–978
   PubMed Web of Science ®Google Scholar
• Mimeault M, Venkatraman G, Johansson SL, Moore E, Henichart JP, Depreux P, Lin MF, Batra SK. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int J Cancer 2007c; 120: 160–169
   Google Scholar
• Nakabayashi M, Oh WK. Chemotherapy for high-risk localized prostate cancer. BJU Int 2006; 97: 679–683
   Google Scholar
• Nikitin AY, Matoso A, Roy-Burman P. Prostate stem cells and cancer. Histol Histopathol 2007; 22: 1043–1049
   Google Scholar
• Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25: 1696–1708
   PubMed Web of Science ®Google Scholar
• Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. Hierarchical organization of prostate cancer cells in xenograft tumors: The CD44+{alpha}2{beta}1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007; 67: 6796–6805
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513–1520
   PubMed Web of Science ®Google Scholar
• Pourpak A, Landowski TH, Dorr RT. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. J Pharmacol Exp Ther 2007; 321: 1109–1117
   PubMed Web of Science ®Google Scholar
• Rizzo S, Attard G, Hudson DL. Prostate epithelial stem cells. Cell Prolif 2005; 38: 363–374
   Google Scholar
• Sanchez P, Hernandez AM, Stecca B, Kahler AJ, DeGueme AM, Barrett A, Beyna M, Datta MW, Datta S, Altaba A. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci USA 2004; 101: 12561–12566
   PubMed Web of Science ®Google Scholar
• Sanchez P, Clement V, Altaba AR. Therapeutic targeting of the Hedgehog-GLI pathway in prostate cancer. Cancer Res 2005; 65: 2990–2992
   PubMed Web of Science ®Google Scholar
• Schalken JA, van Leenders G. Cellular and molecular biology of the prostate: Stem cell biology. Urology 2003; 62: 11–20
   PubMed Web of Science ®Google Scholar
• Sharifi N, Kawasaki BT, Hurt EM, Farrar WL. Stem cells in prostate cancer: Resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biol Ther 2006; 5: 901–906
   PubMed Web of Science ®Google Scholar
• Sheng T, Li C, Zhang X, Chi S, He N, Chen K, McCormick F, Gatalica Z, Xie J. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer 2004; 3: 29
   PubMed Web of Science ®Google Scholar
• Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. Sonic hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 2007; 26: 5674–5679
   PubMed Web of Science ®Google Scholar
• Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002; 94: 1457–1465
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885–4892
   PubMed Web of Science ®Google Scholar
• Sugita S, Kawashima H, Tanaka T, Kurisu T, Sugimura K, Nakatani T. Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor. Oncol Rep 2004; 11: 1273–1279
   Google Scholar
• Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R, Jeter C. Prostate cancer stem/progenitor cells: Identification, characterization, and implications. Mol Carcinog 2007; 46: 1–14
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–1512
   PubMed Web of Science ®Google Scholar
• van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001; 195: 563–570
   PubMed Web of Science ®Google Scholar
• van Leenders GJ, Gage WR, Hicks JL, van Balken B, Aalders TW, Schalken JA, De Marzo AM. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 2003; 162: 1529–1537
   PubMed Web of Science ®Google Scholar
• Wang J, Halford S, Rigg A, Roylance R, Lynch M, Waxman J. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 2000; 86: 675–680
   PubMed Web of Science ®Google Scholar
• Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA 2006; 103: 1480–1485
   PubMed Web of Science ®Google Scholar
• Wei C, Guomin W, Yujun L, Ruizhe Q. Cancer stem-like cells in human prostate carcinoma cells DU145: The seeds of the cell line?. Cancer Biol Ther 2007; 6: 763–768
   PubMed Web of Science ®Google Scholar
• Winquist E, Waldron T, Berry S, Ernst DS, Hotte S, Lukka H. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: A systematic review from the Cancer Care Ontario Program in evidence-based Care's Genitourinary Cancer Disease Site Group. BMC Cancer 2006; 6: 112
   Google Scholar
• Yamanaka K, Gleave ME, Hara I, Muramaki M, Miyake H. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Mol Cancer Ther 2005; 4: 187–195
   PubMed Web of Science ®Google Scholar
• Ye XC, Choueiri M, Tu SM, Lin SH. Biology and clinical management of prostate cancer bone metastasis. Front Biosci 2007; 12: 3273–3286
   Google Scholar
• Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005; 113: 619–628
   PubMed Web of Science ®Google Scholar
• Zhou W, Grandis JR, Wells A. STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines. Br J Cancer 2006; 95: 164–171
   Google Scholar
• Zhou Z, Flesken-Nikitin A, Nikitin AY. Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. Cancer Res 2007; 67: 5683–5690
   PubMedGoogle Scholar
• Zoorob RJ, Cender D. A different look at corticosteroids. Am Fam Physician 1998; 58: 443–450
   PubMed Web of Science ®Google Scholar